AMARANTUS BIOSCIENCE HOLDINGS, INC. BALANCE SHEET (Unaudited)

Transcription

1 AMARANTUS BIOSCIENCE HOLDINGS, INC. BALANCE SHEET (Unaudited) December 31, 2017 ASSETS Current assets: Cash and cash equivalents 47,204 Related party convertible notes receivable at fair value 598,695 Prepaid expenses and other current assets 792,580 Total current assets 1,438,479 Non-current assets: Property and equipment, net - Investment in Avant at fair value 8,800,000 Total non-current assets 8,800,000 TOTAL ASSETS 10,238,479 LIABILITIES AND STOCKHOLDERS DEFICIT AND TEMPORARY EQUITY Current liabilities: Accounts payable and accrued liabilities 17,581,376 Notes payable 706,265 Convertible Notes 9,492,416 Share-settled debt 475,109 Total current liabilities 28,255,166 Total liabilities 28,255,166 Common and Preferred Stock 19,604,032 Additional paid-in capital 81,980,189 Accumulated deficit (115,163,269) Net Income (4,437,639) Total stockholders' equity (18,016,687) TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT AND TEMPORARY EQUITY 10,238,479

2 AMARANTUS BIOSCIENCE HOLDINGS, INC. STATEMENTS OF OPERATIONS (unaudited) December 31, 2017 Net revenues: $ - Operating expenses: Research and development - General and administrative 3,214,711 Total operating costs and expenses 3,214,711 Loss from operations (3,214,711) Other income (expense): Interest Income 45,620 Interest Expense (1,266,764) Other expense (1,784) Total other income (expense) (1,222,928) Net loss (4,437,639)

3 Cash flows from operating activities AMARANTUS BIOSCIENCE HOLDINGS, INC. STATEMENTS OF CASH FLOWS (Unaudited) December 31, 2017 Net loss $ (4,437,639.29) Adjustments to reconcile net loss to net cash used in operating activities Depreciation and amortization 17,240 Changes in assets and liabilities: Prepaid expenses and other current assets 473,745 Accounts payable and accrued expenses 2,000,884 Net cash used in operating activities 2,474,629 Net increase in cash and cash equivalents (2,018) Cash and cash equivalents, beginning of the year 49,221 Cash and cash equivalents, end of period $ 47,204

4 AMARANTUS BIOSCIENCE HOLDINGS, INC. NOTES TO FINANCIAL STATEMENTS (Unaudited) Note 1 Organization and Description of Business Amarantus Bioscience Holdings, Inc. ( Amarantus or the Company ) is a California based biopharmaceutical company founded in January The Company owns or has exclusive licenses to various product candidates in the biopharmaceutical and diagnostic areas of the healthcare industry. The Company is developing our diagnostic product candidates in the field of neurology, and its therapeutic product candidates in the areas of neurology, psychiatry, ophthalmology and regenerative medicine. The Company s business model is to develop its product candidates through various de-risking milestones that the Company believes will be accretive to shareholder value, and will position them to be strategically partnered with pharmaceutical companies, diagnostic companies and/or other stakeholders in order to more efficiently achieve regulatory approval and commercialization. Note 2 Going Concern The Company s activities since inception have consisted principally of acquiring product and technology rights, raising capital, and performing research and development. Successful completion of the Company s development programs and, ultimately, the attainment of profitable operations are dependent on future events, including, among other things, its ability to access potential markets; secure financing; develop a customer base; attract, retain and motivate qualified personnel; and develop strategic alliances. From inception, the Company has been funded by a combination of equity and debt financings. Although management believes that the Company will be able to successfully fund its operations, there can be no assurance that the Company will be able to do so or that the Company will ever operate profitably. The Company s activities since inception have consisted principally of acquiring product and technology rights, raising capital, and performing research and development. Historically, we have incurred net losses and negative cash flows from operations. The Company expects to continue to incur substantial losses over the next several years during its development phase. To fully execute its business plan, the Company will need to complete certain research and development activities and clinical studies. Further, the Company s product candidates will require regulatory approval prior to commercialization. These activities may span many years and require substantial expenditures to complete and may ultimately be unsuccessful. Any delays in completing these activities could adversely impact the Company. The Company plans to meet its capital requirements primarily through issuances of debt and equity securities and, in the longer term, revenue from product sales. The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America ( GAAP ), which contemplate continuation of the Company as a going concern. Historically, the Company has incurred net losses and negative cash flows from operations. The Company believes its current capital resources are not sufficient to support its operations. Management intends to continue its research efforts and to finance operations of the Company through debt and/or equity financings. Management plans to seek additional debt and/or equity financing through private or public offerings or through a business combination or strategic partnership; provided, however, here can be no assurance that the Company will be successful in obtaining additional financing on favorable terms, or at all. These matters raise substantial doubt about the Company s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of these uncertainties.

5 Note 3 Summary of Significant Accounting Policies Significant Accounting Policies - There have been no material changes in the Company s significant accounting policies, other than the Fair Value of Convertible Notes Receivable, to those previously disclosed in the 2016 Annual Report. Reclassification - Certain amounts in the prior period financial statements have been reclassified to conform to the presentation of the current period financial statements. These reclassifications had no effect on the previously reported net loss. Basis of Presentation - The Financial Statements and related disclosures have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission ( SEC ). The Financial Statements have been prepared using the accrual basis of accounting in accordance with GAAP (See Note 2) regarding the assumption that the Company is a going concern. Development Stage Company - The Company is a development stage company as defined by section of the FASB Accounting Standards Codification. The Company is still devoting substantially all of its efforts on establishing the business. Its planned principal operations have not commenced. All losses accumulated since inception have been considered as part of the Company s development stage activities. Use of Estimates - The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of expenses during the reporting period. Significant estimates include the fair value of notes receivable and derivatives, the fair value of stock-based compensation and warrants, the carrying value of intangible assets (patents and licenses), valuation allowance against deferred tax assets, and related disclosure of contingent assets and liabilities. Actual results could differ from those estimates. Research and Development Expenditures - Research and development costs are expensed as incurred. Research and development costs include salaries and personnel-related costs, consulting fees, fees paid for contract research services, fees paid to clinical research organizations and other third parties associated with clinical trials, the costs of laboratory equipment and facilities, and other external costs. The Company incurred no research and development expenses for the year ended December 31, Fair Value Option - The Company has elected the fair value option to account for its convertible note receivable and its investments at fair value with changes in fair value recorded in the statement of operations. Fair Value Convertible Notes Receivable - The Company s convertible note receivable as of December 31, 2017 was valued, taking into consideration, cost of the investment, market participant inputs, market conditions, liquidity, operating results and other qualitative and quantitative factors. The values at which the Company s convertible note receivable are carried on its books are adjusted to estimated fair value at the end of each quarter taking into account general economic and stock market conditions and those characteristics specific to the underlying investments. Due to the short term nature of convertible note receivable, cost approximates fair value. Investments Investments in entities where the Company can exercise significant influence, but not control, is classified as an equity investment and accounted for using the fair value option. Recent Accounting Pronouncements Except for rules and interpretive releases of the SEC under authority of federal securities laws and a limited number of grandfathered standards, the FASB Accounting Standards Codification ( ASC ) is the sole source of authoritative GAAP literature recognized by the FASB and applicable to the Company. We have reviewed the FASB issued Accounting Standards Update ( ASU ) accounting pronouncements and interpretations thereof that have effectiveness dates during the periods reported and in future periods. The Company has carefully considered the new pronouncements that alter previous GAAP and does not believe that any new or modified principles will have a

6 material impact on the Company s reported financial position or operations in the near term. The applicability of any standard is subject to the formal review of our financial management and certain standards are under consideration. Note 4 Net Loss per share The Company computes basic and diluted earnings per share amounts in accordance with ASC Topic 260, Earnings per Share. Basic earnings per share is computed by dividing net income (loss) available to common shareholders by the weighted average number of common shares outstanding during the reporting period. Diluted earnings per share reflects the potential dilution that could occur if stock options and other commitments to issue common stock were exercised or equity awards vest resulting in the issuance of common stock that could share in the earnings of the Company. Note 5 Fair Value of Financial Instruments The Company s balance sheet includes certain financial instruments. The carrying amounts of current assets and current liabilities approximate their fair value because of the relatively short period of time between the origination of these instruments and their expected realization. The Company follows FASB ASC 820 Fair Value Measurements and Disclosures which defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy that distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity s own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy are described below: Level 1 - Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities. Level 2 - Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly, including quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability (e.g., interest rates); and inputs that are derived principally from or corroborated by observable market data by correlation or other means. Level 3 - Inputs that are both significant to the fair value measurement and unobservable. Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of December 31, The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments. These financial instruments include accounts receivable, other current assets, accounts payable, accrued compensation and accrued expenses. The fair value of the Company s notes payable is estimated based on current rates that would be available for debt of similar terms which is not significantly different from its stated value. Note 6 Convertible Notes Receivable Notes receivable are stated at fair value, as the Company has elected to fair value its notes receivable using the fair value option permitted to the Company. The following is a summary of outstanding convertible notes receivable as of December 31, 2017.

7 Stated Conversion Carrying Issue Date Maturity Date Interest Rate Terms Value Avant Diagnostics, Inc 3/7/2016 3/7/ % $ 0.20 $ 100,000 Theranostics Health, Inc 2/29/2016 2/28/2017 8% $ ,000 Ending balance as of December 31, 2017 $ 500,000 During the year ended on December 31, 2017, the Company received payment in the amount of $86,000 with respect to the note with Avant Diagnostics Inc. Notes 7 Notes Payable As of December 31, 2017, the Company had notes payable in the aggregate amount of $706,265 outstanding. On April 6, 2017, the Company issued a 12% Senior Secured Convertible Note (the Secured Note ) to Xpress Group International Limited (the Investor ) in the principal amount of $100,000 pursuant to a Securities Purchase Agreement dated April 6, 2017 (the SPA ). The Secured Note matures on October 6, 2017 (the Maturity Date ) and shall accrue interest at a rate equal to 12% per annum. The Secured Note contains certain customary events of default (including, but not limited to, default in payment of principal or interest thereunder or a material breach of any transaction document). Upon the occurrence of any such event of default the outstanding principal amount of the Secured Note, plus accrued but unpaid interest and other amounts owing in respect thereof through the date of acceleration, shall become immediately due and payable. The Secured Note is convertible at any time into either Company common stock at a fixed conversion price of $ per share or common shares of Avant Diagnostics, Inc. ( Avant ) owned by the Company at a conversion price of $0.16 per share. If the market price of Avant common stock based on an average of the closing trading price of Avant common stock for the five trading days immediately prior to the Conversion Date (the Avant Conversion Market Price ) is less than $0.32, then the Investor shall receive additional shares of Avant common stock such that the total amount of Avant common stock received by the Investor as of the conversion date, when valued at the Avant Conversion Market Price, will equal the conversion amount up to a maximum total of 5.5 million shares of Avant common stock. On October 5, 2017, the Company and the Investor extended the Maturity Date of the Secured Note to April 24, On the Maturity Date, all outstanding principal and accrued and unpaid interest shall be converted into Company common stock. On April 6, 2017 the Company entered into the Second Amendment To Intercreditor And Subordination Agreement ( Second Amendment ), by and among the, the Company, all of the subsidiaries of the Company (such subsidiaries, the Subsidiaries, the Company jointly and severally, together with their respective successors and assigns, collectively, the Debtors ), GEMG LLC, Anson Investments Master Fund LP, Dominion Capital, LLC and Delafield Investments Limited ( Delafield ), the holders of the Company s 12% Senior Secured Convertible Promissory Notes in the original aggregate principal amount of approximately $9,215,000 pursuant to the Senior Loan Agreement, Delafield in its capacity as collateral agent and the Investor pursuant to which the Secured Note and any subsequent amounts invested by the Investor in the Company in the form of a secured note shall be subject to Second Amendment. Additionally the Company entered into Amendment No. 1 to the Pledge Agreement dated October 31, 2016 between the Company and the Investor (the Pledge Agreement Amendment ) pursuant to which the Company s obligation under the Secured Note is secured by 5.5 million shares of Avant common stock owned by the Company. The Investor is a corporation owned by Mr. Chan Heng Fai. Mr. Chan is also the owner of Amarantus Bioscience PTE, Ltd., the controlling shareholder of the Company. In addition, Mr. Chan is the Chief Executive Officer of Singapore edevelopment Limited. Pursuant to a non-binding Letter of Intent entered into in February of 2017 between the Company and SeD Biomedical Inc., a subsidiary of Singapore edevelopment Limited, SeD Biomedical Inc. agreed to inject certain assets into the Company, subject to certain contingencies, including, but not limited to, the completion of due diligence and the execution of definitive agreements. Pursuant to the non-binding Letter of Intent, SeD

8 Biomedical is entitled to nominate certain director nominees to the Company s Board of Directors and has named four of the Company s current eight directors. The directors named by SED BioMedical Inc. recused themselves from all deliberations regarding the Secured Note, the SPA, the Second Amendment and the Pledge Agreement Amendment. The foregoing summaries of the Secured Note, SPA, Second Amendment and the Pledge Agreement Amendment do not purport to be complete and are qualified in their entirety by reference to the copies of the Secured Note, SPA, Second Amendment and the Pledge Agreement Amendment. The Company is in default under the terms of all its senior secured convertible promissory notes. On November 6, 2017, the Company entered into a securities purchase agreement (the November SPA ) with an accredited investor pursuant to which the Company issued such investor a secured convertible note (the Note ) in the principal amount of $100,000. Pursuant to the terms of the November SPA, until the Note is no longer outstanding, the Company may not, without the consent of the holder thereof, enter into any Equity Line of Credit (as defined in the November SPA), issue or agree to issue floating or Variable Priced Equity Linked Instruments (as defined in the November SPA) or issue or agree to issue any of the foregoing or equity with price reset rights. Furthermore, (i) subject to certain exceptions, until 12 months after the closing date, the holder of the Note shall have the right to participate in up to 100% of any subsequent financing and (ii) for a period of 180 days following the closing or until such time when Rule 144 becomes available for the resale of the shares of common stock issuable upon conversion of the Note, if the Company files a registration statement with the SEC, the holder of the Note may request that the shares of common stock issuable upon conversion of the Note be registered in such registration statement. Subject to certain exceptions, in the event the Company issues or sells any shares of common stock or common stock equivalents with better terms and conditions granted to the holder of the Note, upon notice to the Company, the Company shall amend the terms of the transaction documents so as to give the holder of the Note the benefit of such more favorable terms or conditions. Share Settled Debt No activity in the year ended December 31, Note 8 Stockholder s Equity Common Stock Purchase Warrants The following table summarizes the Company s warrant activities for the year ended December 31, 2017: Weighted Average Number of Weighted Average Remaining Warrants Exercise Price Contractual Term Outstanding as of January 1st, ,809,950 $ Issued in connection with various financings (1) 14,744, Reset warrants (2) 25,284, Issued in connection with various financings 2,750, Outstanding as of December 31, ,589, $ 4.41 (1) The warrants contain down round protection and the Company classifies these warrant instruments as liabilities at their fair value and adjusts the instruments to fair value at each reporting period.

9 Note 9 Temporary Equity Series E Preferred Stock The following table summarizes the Company s Series E Preferred Stock activities for the year ended December 31, 2017 (amount in thousands): Series E convertible preferred stock Shares Par value Balances as of January 1, $ - Reclass Series E to temparay equity 9,766 8,764 Proceeds from sale of Series E preferred stock Common stock issued in conversion of Series E convertible preferred stock (1,335) (1,335) Deemed dividends on conversion of Series E convertible preferred stock to common stock Repurchase of Series E preferred stock (413) (413) Offering cost related to repurchase of Series E preferred stock - (10) Deemed dividends on repurchase of Series E convertible preferred stock - 45 Deemed dividends related to accretion of redemption value - 2,873 Offering cost - (51) Balance as of December 31, ,274 $ 10,243 Series H Preferred Stock The following table summarizes the Company s Series H Preferred Stock activities for the year ended December 31, 2017 (amount in thousands): Series H convertible preferred stock Shares Par value Balances as of January 1, ,816 $ 3,154 Series H preferred stock issued for note conversion Proceeds from sale of Series H preferred stock, net of issuance cost of $0.5 million 4,883 3,890 Beneficial conversion feature of Series H convertible preferred stock - (610) Deemed dividends related to immediate accretion of beneficial conversion feature of Series H convertible preferred stock Fair Value of common stock warrant issued with Series H convertible preferred stock - (1,456) Common stock issued in conversion of Series H convertible preferred stock (1,724) (1,724) Deemed dividends on conversion of Series H convertible preferred stock to common stock - 1,058 Repurchase of Series H convertible preferred stock (413) (413) Offering cost related to repurchase of Series H convertible preferred stock - (10) Deemed dividends on repurchase of Series H convertible preferred stock - 48 Deemed dividends related to accretion of redemption value - 3,651 Balance as of December 31, ,672 $ 8,297 Note 10 Related Party Transactions Convertible Notes Receivable See Note 6 for a discussion of convertible notes receivable. Notes Payable The Company has a demand promissory note with Neurotrophics. At the option of the Company, the note and the accrued interest owed thereunder may be repaid by issuing shares of the Company s common stock based on the closing price of the Company s common stock on the day of the conversion. If converted on December 31, 2017, the

10 conversion price would be $0.05 per share and would convert into approximately 5.2 million shares of the Company s common stock. Note 11 Subsequent Event On January 8, 2018, the holders of a majority of the Company s outstanding Senior Secured Convertible Debentures (the Senior Debt ) and Series E and Series H Convertible Preferred Stock (the Preferred Stock and together with the Senior Debt, the Securities ) granted the Company a 45-extension to the previously announced Forbearance and Capital Restructuring Binding Letters of Intent ( LOIs ) between the Company and a majority of the Security holders to restructure the Securities to allow the Company to complete its capital restructuring effort and financing under the newly-adopted holding company business model (the Securities Restructuring ). Pursuant to the extension, the last date to initiate the tender exchange was February 24, On February 25, 2018, the Company entered into definitive agreements for the sale of up to $1,500,000 shares of the Company s Series I Convertible Preferred Stock (the Series I Preferred Stock ). Pursuant to the terms of the securities purchase agreement, the investor shall purchase up to 300 shares of Series I Preferred Stock, with a stated value of $1,000 per share, in multiple tranches for up to $300,000 in gross proceeds. Each share of Series I Preferred Stock is convertible into common stock at a fixed price of $0.07 per share, subject to adjustment. The Company may repurchase all outstanding shares of Preferred Stock at any time pursuant to the terms of the agreement. On February 25, 2018, the Company opened the exchange period contemplated under LOIs with respect to the tender exchange with the holders of the Securities (the Tender Exchange ). Holders of 96% of the Securities eligible to participate in the Tender Exchange have executed the LOIs acknowledging their participation in the Company's recapitalization effort. Holders of the remaining 4% of the Securities eligible to participate in the Tender Exchange may participate until the expiration of the exchange period which was anticipated to be March 17, 2018; however, such period was extended to March 28, On March 28, 2018, the Company completed the Tender Exchange with the Securities holders. Pursuant to the terms of the LOIs and exchange agreements, holders of an aggregate of approximately $8.43 million in Senior Debt ("Old Debt") received new senior secured convertible notes in the aggregate principal amount of approximately $6.74 million ("New Secured Debt") and holders of an aggregate of approximately $13.91 million in Preferred Stock received new unsecured convertible note in the aggregate principal amount of approximately $10.43 million ("New Unsecured Debt" and together with the New Secured Debt, the "New Debt"). The New Debt holders have agreed to a moratorium of conversion of the New Debt into equity securities for a period of nine months from the closing of the Tender Exchange. Concurrently with the Tender Exchange, warrants to purchase an aggregate of 53,598,394 shares of the Company s common stock were canceled, leaving warrants to purchase an aggregate of 1,532,644 shares of the Company s common stock outstanding immediately following the consummation of the Tender Exchange. Upon closing and settlement of capital equal to or greater than $5 million in the Company, there will be a release by holders of the New Secured Debt of all security interests in the Company's assets, and holders of New Debt will convert such debt into a newly designated class of preferred stock (the "New Preferred Stock") (with such conversion conditioned upon the reduction of Company s accounts payable balance to less than $2 million with no single account payable exceeding $100,000), thereby improving the Company's equity balance sheet in preparation for the anticipated listing of the Company's common stock on a national exchange. Additionally, upon completion of a capital raise equal to or greater than $1 million at any subsidiary level to independently fund such subsidiaries' operations, the holders of the New Secured Debt shall release all of the security interests in such subsidiary's assets; provided, however, the foregoing release of security interests of subsidiaries of the Company shall not be applicable to Amarantus BioLife, Inc. The holders of the New Debt and the New Preferred Stock may convert such securities at the earlier of (i) nine months from the closing date of the Tender Exchange ("Conversion Date") or (ii) upon the price of the Company s common stock reaching 250% of the price at which the Company began trading on a national exchange. The holders of the New Debt and New Preferred Stock will be eligible to convert approximately 25% of the principal amount of the related position (notes or preferred) starting on the Conversion Date for liquidation over a four month interval ("Liquidation Interval"), and subsequently for conversion of the next 25% and liquidation over the same intervals thereafter over the next three successive four month periods. The conversion price of the New Preferred Stock will be the average price of the Company s common stock for the immediately preceding twelve trading days, subject to an

11 increase cap of 250% of the uplist price. The converted shares will be subject to a liquidation limit for each Liquidation Interval of each 25% of the position equal to the greater of (i) 5% of the average trading volume for the prior five days or (ii) % of the daily average trading volume. All securities delivered in the Tender Exchange shall be assigned to a Special Purpose Vehicle to be formed by the Company (the "AMBS SPV"), for the benefit of each holder of the securities, and the AMBS SPV shall be solely responsible for the administration and liquidation of the Company securities (conversion shares) for remittance of proceeds. Holders of the New Secured Debt will receive an aggregate of 79,250,000 share of common stock of Avant that the Company currently owns, with such shares being deposited to an separate Special Purpose Vehicle to be formed by the Company (the "AVDX SPV") specifically for the purpose of ensuring the orderly liquidation of such AVDX shares to be held by the New Secured Debt holders, with the proceeds from such sales being used to redeem in part, or in whole, the then outstanding balance of New Secured Debt or New Preferred Stock. In the event the Company sells any shares of its subsidiaries, the Company has agreed to use 50% of the proceeds from such sales to redeem the balances in the AMBS SPV. The Company reserves the right to redeem all outstanding New Debt in the AMBS SPV for cash at any time. As of April 16, 2018, an additional $350,000 in Preferred Stock executed agreement to participate in the Tender Exchange, bringing the total participation over 97.5% of the eligible Securities.